Evaluation of the Safety and Effectiveness of Percutaneous and Transbronchial Argon-helium Cryoablation

Exclusion Criteria

• •Serious cardio-cerebral disease or other mental diseases
• •Severe pulmonary fibrosis, especially drug-induced pulmonary fibrosis
• •Patients with previous severe pulmonary dysfunction, pulmonary ventilation disorder and multiple pulmonary bullae
• •Have a history of immunodeficiency, including HIV test (enzyme-linked immunosorbent assay and Western blotting) positive
• •Chemotherapy, radiotherapy, interventional therapy, ablation and surgical treatment within 30 days before surgical treatment
• •There is a tendency to severe bleeding, and the platelet is less than 50 × 109/L and severe disorder of coagulation function
• •Coagulation index (PT, TT, APTT)\>2.5 times of the upper normal limit
• •Malignant pleural effusion on the same side of the ablation focus was not well controlled
• •Poor general condition, multiple organ failure, cachexia, severe anemia and nutritional metabolism disorder
• •Those who have extensive extrapulmonary metastasis and are not suitable for ablation treatment
• •Those who often use sedatives, sleeping pills, tranquilizers or other addictive drugs
• •Pregnant or lactating women
• •Those who can not judge the curative effect
• •Other conditions determined by the researcher to be unsuitable for the group, such as inability to tolerate cryoablation, difficulty in follow-up, and other serious diseases